Brief: Biomea Fusion Highlights Initial Data From The First Two Type 1 Diabetes Patients Dosed With BMF-219
01/04/2024 17:32
April 1 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION HIGHLIGHTS INITIAL DATA FROM THE FIRST TWO
TYPE 1
DIABETES PATIENTS DOSED WITH BMF-219
* BIOMEA FUSION INC: BMF-219 HAS BEEN WELL TOLERATED BY BOTH
PATIENTS
* BIOMEA FUSION: FIRST TWO TYPE 1 DIABETES PATIENTS IN
STUDY
SHOWED EARLY SIGNS OF CLINICAL ACTIVITY WITH IMPROVED MEASURES
OF BETA-CELL FUNCTION
* BIOMEA FUSION: OPEN LABEL PORTION OF PHASE II COVALENT-112
STUDY
READOUT OF 40 PATIENTS WITH TYPE 1 DIABETES DOSED FOR 12 WEEKS
EXPECTED IN 2024
Source text for Eikon: ID:nGNXbFf9CC
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes